Table 2.

Treatment characteristics

ADT
Concomitant ADT	83 (83%)
Duration ADT
< 6 months	18 (18%)
6–12 month	22 (22%)
12–24 month	17 (17%)
> 24 months	22 (22%)
Unknown	4 (4%)
RT
Dose to prostatic fossa EQD21.5 Gy (Gy), median (range)	66 (60–70)
Dose to local recurrence EQD21.5 Gy (Gy), median (range)	70 (66–72)
Dose to lymphatic pathways EQD21.5 Gy (Gy), median (range)	47.5 (42.4–50.9)
Dose to PET-pos. lymph nodes EQD21.5 Gy (Gy), median (range)	65.1 (56–66)

Abbreviations: ADT androgen deprivation therapy; RT radiotherapy